sarscov
identifi
etiolog
agent
acut
respiratori
diseas
caus
atyp
pneumonia
diarrhea
averag
mortal
sarscov
zoonot
viru
cross
speci
barrier
like
origin
bat
grown
speci
notabl
civet
viru
emerg
guangdong
provinc
china
late
rapidli
spread
countri
juli
communityacquir
laboratoryacquir
sar
case
report
http
wwwwhointcsrsarsen
human
cov
hcov
sarscov
hong
kong
univers
cov
sarscov
caus
sever
diseas
virus
circul
bat
differ
contin
addit
sarscov
could
use
biolog
weapon
declar
categori
c
prioriti
pathogen
nation
institut
allergi
infecti
diseas
biodefens
http
wwwniaidnihgovbiodefensebandcpriorityhtml
defin
efficaci
therapi
yet
avail
sar
possibl
reemerg
viru
due
presenc
high
number
bat
differ
contin
infect
sarscov
ancestor
realist
one
therefor
design
effect
safe
vaccin
protect
sar
still
high
prioriti
vaccin
base
whole
purifi
inactiv
viru
benefit
present
complet
repertoir
viral
antigen
although
inactiv
vaccin
gener
provid
longlast
immun
vaccin
provid
good
protect
mice
hamster
partial
protect
ferret
rhesu
monkey
formaldehydeinactiv
sarscov
vaccin
show
partial
protect
inactiv
sarscov
vaccin
also
administ
human
vaccin
safe
induc
neutral
antibodi
efficaci
data
report
overal
inactiv
vaccin
base
whole
purifi
viru
induc
neutral
antibodi
appar
safe
least
young
anim
model
provid
good
protect
subunit
vaccin
advantag
simplic
chemic
definit
lack
potenti
variabl
case
sarscov
great
advantag
welldefin
protein
domain
bind
cell
receptor
human
angiotensin
convert
enzym
provid
full
immun
protect
concept
reinforc
observ
monoclon
antibodi
specif
receptor
bind
domain
elicit
protect
sever
anim
model
includ
african
green
monkey
addit
domain
peptid
protein
larg
protein
sarscov
expos
envelop
also
elicit
viru
neutral
antibodi
could
use
improv
subunit
vaccin
furthermor
immun
sarscov
also
demonstr
viruslik
particl
vlp
overal
result
obtain
subunit
vaccin
strongli
suggest
protect
sar
vaccin
feasibl
dna
vaccin
safe
nonexpens
often
effici
larg
mammal
dna
vaccin
induc
sarscov
neutral
antibodi
protect
mice
use
viral
vector
protect
sar
extens
explor
adenoviru
induc
good
protect
mice
modifi
vaccinia
ankara
mva
provid
protect
mice
ferret
although
induct
antibodydepend
enhanc
diseas
ade
report
adenoassoci
viru
induc
longterm
protect
sarscov
parainfluenza
viru
elicit
protect
hamster
monkey
recombin
measl
virus
express
protein
sarscov
induc
neutral
antibodi
immun
respons
sarscov
newcastl
diseas
recombin
viru
express
protein
sarscov
induc
neutral
antibodi
african
green
monkey
immun
via
respiratori
tract
recombin
attenu
vesicular
stomat
viru
vsv
protect
mice
sarscov
challeng
month
vaccin
venezuelan
equin
enceph
vee
viru
express
protein
sarscov
induc
protect
challeng
virul
viru
mous
model
overal
result
indic
good
prospect
develop
efficaci
safe
vaccin
prevent
sar
nevertheless
relev
aspect
need
improv
order
achiev
vaccin
fulli
protect
free
side
effect
young
elderli
peopl
sarscov
envelop
singlestrand
positivesens
rna
viru
genom
kb
belong
genu
coronavirida
fig
replicas
gene
encod
within
twothird
sarscov
genom
includ
two
overlap
open
read
frame
orf
name
orf
latter
translat
ribosom
frameshift
upstream
orf
stop
codon
fig
translat
orf
cytoplasm
infect
cell
result
synthesi
two
polyprotein
process
two
viral
proteinas
yield
function
nonstructur
protein
nsp
nsp
compon
membraneanchor
complex
cov
encod
speciesspecif
accessori
gene
downstream
orf
remark
conserv
order
replicasetranscriptas
spike
envelop
e
membran
nucleocapsid
n
lipid
bilay
envelop
contain
least
three
protein
e
coordin
virion
assembl
releas
larg
peplom
fig
glycoprotein
locat
virion
surfac
confer
viru
characterist
corona
shape
main
mediat
host
cell
attach
entri
sarscov
orf
encod
addit
viru
membran
protein
accessori
protein
function
accessori
protein
still
unclear
howev
known
protein
influenc
interact
viral
pathogenesi
sarscov
molecul
serv
receptor
also
implic
altern
receptor
entri
e
gene
nonessenti
genu
mhv
cov
although
elimin
gene
mhv
genom
reduc
viru
growth
cell
cultur
contrast
group
tgev
coronaviru
express
e
gene
product
essenti
viru
releas
spread
propag
e
tgev
restor
provid
e
protein
tran
recombin
sarscov
rsarscov
lack
e
gene
gener
bac
fig
recov
vero
cell
rel
high
titer
around
pfuml
also
cell
low
titer
indic
sarscov
e
protein
essenti
viru
replic
cell
cultur
electron
microscopi
observ
vero
cell
infect
sarscov
wt
delet
mutant
show
higher
effici
assembl
releas
wt
viru
fig
respect
behav
like
mhv
although
grow
consider
higher
titer
vaccin
viabil
efficaci
requir
product
virus
high
titer
interestingli
adapt
viru
grow
vero
cell
passag
led
increas
viru
titer
reach
valu
almost
ident
display
fulllength
viru
around
pfuml
titer
close
requir
competit
live
attenu
vaccin
sarscov
infect
replic
sever
speci
includ
mice
ferret
hamster
nonhuman
primat
anim
develop
inappar
mild
diseas
ideal
anim
model
complet
reproduc
human
clinic
diseas
patholog
find
identifi
evalu
vaccin
candid
use
three
anim
model
system
hamster
transgen
mice
express
receptor
human
sarscov
convent
mice
challeng
mouseadapt
viru
anim
model
system
complementari
hamster
model
use
studi
viru
pathogen
demonstr
element
present
human
case
sarscov
infect
includ
interstiti
pneumon
consolid
hamster
model
reproduc
support
sarscov
replic
respiratori
tract
higher
titer
longer
durat
mice
nonhuman
primat
viru
replic
model
accompani
histolog
evid
pneumon
anim
develop
viremia
extrapulmonari
spread
viru
although
overt
clinic
diseas
absent
hamster
model
use
model
evalu
sarscov
infect
titer
recombin
sarscov
rsarscov
achiev
respiratori
tract
hamster
similar
previous
report
wildtyp
viru
least
higher
titer
viru
suggest
mutant
viru
attenu
histopatholog
examin
lung
infect
hamster
show
reduc
amount
viral
antigen
pulmonari
inflamm
infect
rsarscov
infect
anim
indic
attenu
vivo
fact
reduct
sarscov
titer
patient
associ
consider
reduct
pathogen
increas
surviv
rate
immun
hamster
remain
activ
follow
wildtyp
viru
challeng
mock
immun
display
decreas
activ
transgen
mice
model
base
product
mice
express
receptor
human
sarscov
transgen
mice
model
obtain
differ
laboratori
express
control
differ
promot
mice
develop
moder
respiratori
diseas
overwhelm
neurolog
diseas
mortal
intranas
infect
sarscov
use
assess
attenu
vaccin
safeti
efficaci
previous
show
infect
highli
suscept
mice
rsarscov
e
sever
groupspecif
protein
gene
delet
rsarscov
result
neither
weight
loss
death
even
inocul
high
viru
dose
mouseadapt
sarscov
model
use
evalu
base
recent
isol
sarscov
adapt
growth
mice
rat
model
provid
use
system
vaccin
evalu
strain
mice
rat
infect
virus
develop
sever
respiratori
diseas
even
death
mouseadapt
strain
isol
passag
lung
balbc
mice
strain
unlik
parent
urbani
strain
viru
intranas
inocul
viru
result
sign
respiratori
diseas
substanti
mortal
show
immun
almost
complet
protect
balbc
mice
fatal
respiratori
diseas
caus
mouseadapt
sarscov
fig
partli
protect
transgen
mice
lethal
diseas
summari
immunogen
protect
efficaci
shown
three
anim
model
system
describ
hamster
highli
suscept
transgen
mice
express
receptor
human
sarscov
convent
mice
challeng
viru
interestingli
homolog
heterolog
protect
observ
fact
hamster
transgen
mice
immun
develop
high
serum
neutral
antibodi
titer
protect
replic
homolog
sarscov
urbani
heterolog
sarscov
upper
lower
respiratori
tract
relev
observ
strain
sarscov
one
serolog
diverg
human
sarscov
identifi
relat
urbani
strain
addit
shown
strain
close
relat
isol
obtain
anim
sarscov
reemerg
would
probabl
anim
origin
despit
attenu
replic
respiratori
tract
viru
immunogen
efficaci
vaccin
hamster
two
mous
model
e
gene
delet
mutant
attenu
two
anim
model
system
hamster
transgen
mice
express
receptor
indic
fact
infect
delet
mutant
led
weight
loss
death
lung
immun
histopatholog
contrast
infect
virul
sarscov
fig
addit
refin
test
viru
virul
perform
hamster
use
activ
wheel
decreas
hamster
activ
detect
day
hamster
infect
sarscov
lack
e
gene
contrast
infect
viru
fulllength
genom
furthermor
infect
brain
infect
transgen
mice
contrast
wt
viru
overal
data
indic
e
virul
gene
potenti
mechan
e
gene
product
virul
investig
laboratori
shown
express
e
gene
drastic
reduc
express
gene
involv
stress
unfold
protein
respons
reduct
stress
respons
associ
decreas
innat
specif
immun
respons
consequ
postul
delet
e
gene
lead
increas
immun
respons
viru
reduc
appar
pathogen
gener
effici
inactiv
live
modifi
vaccin
viru
titer
need
high
order
obtain
econom
competit
vaccin
increas
viru
titer
propos
novel
approach
base
previou
find
show
coronaviru
genom
encod
mutat
exon
display
mutat
phenotyp
engin
sarscov
mutat
delet
e
protein
modifi
includ
exon
caus
accumul
mutat
throughout
viral
genom
mutat
virus
pass
cell
cultur
infect
cell
highest
viru
dilut
possibl
dilut
contain
mutant
virus
highest
titer
therefor
expect
serial
passag
dilut
select
viru
clone
high
titer
desir
viru
titer
achiev
confirm
high
titer
virus
still
attenu
vivo
viru
evolut
revert
standard
level
replac
mutat
nativ
one
use
infecti
cdna
clone
select
virus
test
protect
previous
describ
previous
shown
elicit
protect
immun
respons
time
other
also
shown
possibl
delet
addit
nonessenti
gene
gener
viabl
sarscov
addit
delet
gene
involv
inhibit
ifn
activ
propos
delet
gene
determin
whether
remov
increas
immun
respons
vaccin
candid
sarscov
e
protein
reduc
stress
unfold
protein
immun
respons
viru
postul
effort
enhanc
assembl
level
viral
protein
without
diminish
stress
respons
increas
absenc
e
might
increas
immunogen
without
compromis
safeti
consequ
propos
construct
rsarscov
mutant
modifi
e
protein
e
elicit
higher
immun
respons
viru
mutant
e
code
gene
fulli
function
viru
morphogenesi
insert
within
viral
genom
approach
base
previou
identif
host
protein
bind
sarscov
e
protein
influenc
virusinduc
stress
respons
immun
respons
viru
e
protein
ligand
identifi
coimmun
precipit
mass
spectrometri
studi
previous
report
yeast
twohybrid
technolog
effect
protein
stress
immun
respons
identifi
propos
modifi
specif
e
protein
domain
order
prevent
cell
interact
counteract
induct
strong
immun
respons
rsarscov
vaccin
experiment
inform
influenc
coronaviru
replicas
protein
modif
attenu
obtain
chang
case
sarscov
shown
significantli
inhibit
ifndepend
signal
decreas
phosphoryl
level
littl
effect
modif
sarscov
mutat
result
viru
replic
effici
wildtyp
viru
cell
defect
ifn
respons
replic
strongli
attenu
cell
intact
ifn
respons
thu
like
mutant
lose
virul
reduc
pathogen
altern
mutat
delet
gene
could
introduc
similar
describ
mhv
replicas
led
attenu
cov
phenotyp
type
mutant
could
investig
relev
gener
attenu
sarscov
phenotyp
could
test
vaccin
candid
delet
mhv
sarscov
virus
caus
reduct
peak
titer
singlecycl
growth
assay
well
reduct
viral
rna
synthesi
growth
find
indic
essenti
viru
replic
delet
may
lead
virus
attenu
phenotyp
addit
recent
studi
mhv
suggest
protein
may
function
pathogenesi
therefor
seem
promis
candid
complement
safeti
vaccin
oglycosyl
accessori
protein
amino
acid
form
kpermeabl
channellik
structur
essenti
growth
tissu
cultur
cell
delet
gene
lead
small
reduct
viru
titer
reduct
vitro
vivo
protein
may
also
involv
trigger
high
level
proinflammatori
cytokin
chemokin
product
delet
may
reduc
sarscov
virul
gene
map
distal
posit
gene
therefor
recombin
event
restor
wild
phenotyp
gene
gene
one
event
seem
unlik
coronaviru
transcript
regul
highli
conserv
sequenc
preced
gene
transcript
regulatori
sequenc
trss
almost
ident
sequenc
locat
end
genom
downstream
leader
sequenc
tr
preced
gene
encod
complementari
sequenc
newli
synthes
rna
neg
polar
rna
hybrid
tr
locat
next
leader
process
discontinu
rna
synthesi
typic
cov
altern
approach
develop
safer
recombinationresist
live
coronaviru
vaccin
develop
baric
group
novel
procedur
involv
modif
trss
sarscov
vaccin
strain
sequenc
incompat
tr
known
circul
cov
postul
recombin
event
wt
coronavirus
tr
remodel
sarscov
would
result
genom
contain
incompat
mix
regulatori
sequenc
block
express
subgenom
mrna
use
molecular
clone
sarscov
tr
network
remodel
acgaac
ccggat
rewir
genom
transcript
network
allow
effici
replic
mutant
viru
icsarscrg
icsarscrg
recombin
viru
replic
titer
equival
wt
viru
express
typic
ratio
subgenom
mrna
protein
shown
vaccin
candid
provid
protect
challeng
virul
sarscov
previou
studi
use
anim
cov
provid
experiment
evid
humor
respons
anim
coronavirus
exacerb
diseas
previous
summar
safeti
concern
increas
case
sarscov
two
studi
one
report
antibodi
neutral
human
sarscov
also
enhanc
viru
entri
mediat
two
civet
cat
sarscov
virus
glycoprotein
relat
sarscov
isol
second
report
shown
administr
mvabas
sarscov
vaccin
ferret
mva
alon
follow
live
sarscov
challeng
result
enhanc
hepat
nevertheless
side
effect
describ
studi
sarscov
mice
hamster
ferret
african
green
monkey
gener
immun
vaccin
candid
result
absenc
side
effect
nevertheless
still
three
concern
remain
unaddress
one
specif
viral
protein
sarscov
n
express
venezuelan
equin
enceph
vee
viru
vector
result
enhanc
immunopatholog
follow
viral
challeng
similar
immun
patholog
observ
follow
vaccin
formalininactiv
respiratori
syncyti
viru
rsv
second
main
concern
observ
sarscov
vaccin
provid
protect
absenc
side
effect
young
mice
show
immunopatholog
complic
age
mice
third
consider
vaccin
candid
test
anim
model
fulli
reproduc
clinic
symptom
observ
human
one
except
phase
clinic
trial
human
perform
therefor
sar
vaccin
candid
would
requir
addit
rigor
clinic
immunolog
evalu
use
sarscov
mouseadapt
viru
model
potenti
side
effect
assess
young
age
anim
cov
characterist
strictli
conserv
genom
organ
gene
occur
order
mhv
viru
mutant
gene
encod
structur
protein
locat
differ
order
construct
shown
canon
coronaviru
genom
organ
essenti
vivo
replic
mutant
show
attenu
phenotyp
interestingli
rearrang
viral
gene
may
use
gener
cov
reduc
risk
gener
viabl
virus
recombin
circul
field
virus
fact
potenti
recombin
virus
differ
gene
order
like
lead
nonviabl
virus
lack
essenti
gene
result
degeneraci
genet
code
two
amino
acid
protein
code
sequenc
encod
one
synonym
codon
frequenc
synonym
codon
use
amino
acid
unequ
coevolv
cell
translat
machineri
avoid
excess
use
suboptim
codon
often
correspond
rare
otherwis
disadvantag
trna
result
phenomenon
term
synonym
codon
bia
vari
greatli
evolutionarili
distant
speci
codon
optim
recombin
method
wide
use
improv
crossspeci
express
opposit
direct
reduc
express
intent
introduct
suboptim
synonym
codon
seldom
chosen
de
novo
gene
synthesi
aim
design
stabli
attenu
poliovirus
sarscov
novel
strategi
construct
viru
variant
contain
synthet
replac
viru
code
sequenc
deoptim
synonym
codon
usag
infect
equal
amount
polioviru
particl
reveal
neuroattenu
phenotyp
strike
reduct
specif
infect
polioviru
particl
similar
attempt
made
baric
group
design
sarscov
vaccin
vaccin
candid
provid
protect
mous
model
system
challeng
virul
viru
ralph
baric
person
commun
due
distribut
effect
mani
silent
mutat
larg
genom
segment
codondeoptim
virus
genet
stabl
phenotyp
may
prove
suitabl
attenu
substrat
product
vaccin
product
effect
safe
vaccin
anim
coronavirus
previous
report
satisfactori
contrast
product
inactiv
subunit
vaccin
base
dna
recombin
vector
vaccin
gener
revers
genet
use
sarscov
genom
seem
promis
vaccin
candid
need
test
sarscov
mouseadapt
model
macaqu
case
use
young
age
anim
later
absenc
side
effect
safeti
assess
human
phase
clinic
trial
vaccin
manufactur
tendenc
use
welldefin
inactiv
vaccin
unfortun
approach
limit
efficaci
elicit
immun
respons
rel
short
immunolog
memori
possibl
balanc
efficaci
safeti
develop
rna
replicationcompet
propagationdefect
vaccin
candid
base
viral
replicon
gener
onecycl
virus
use
packag
cell
line
